Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients

J Clin Apher. 2021 Feb;36(1):135-142. doi: 10.1002/jca.21855. Epub 2020 Nov 28.

Abstract

Background: Peripheral blood stem cell (PBSC) collection is important for successful hematopoietic stem cell transplantation. This study aimed to investigate the laboratory parameters associated with the optimal timing of autologous PBSC collection from lymphoma and multiple myeloma patients.

Methods: We retrospectively evaluated data from 1105 PBSC apheresis procedures performed on 379 adult patients at the National Cancer Center between June 2005 and December 2019. Laboratory parameters, including cutoff values for the number of hematopoietic progenitor cells (HPCs) and circulating CD34+ cells, were analyzed to determine their association with CD34+ cell yield.

Results: The pre-apheresis HPC and CD34+ cell count were statistically significant variables associated with harvested CD34+ cell in lymphoma and MM patients. The optimal cutoff values were 18 × 106 /L for pre-HPC count (66.8% sensitivity, 66.4% specificity) and 11/μL for pre-CD34+ cell count (85.8% sensitivity, 87.2% specificity), to achieve CD34+ cell yields ≥ 1.0 × 106 /kg for each apheresis procedure. Moreover, the optimal cutoff values were 23 × 106 /L for pre-HPC count (71.0% sensitivity, 69.0% specificity) and 18/μL for pre-CD34+ cell count (87.5% sensitivity, 86.3% specificity) to achieve CD34+ cell yields ≥ 2.0 × 106 /kg for each apheresis procedure.

Conclusion: HPC count is a potential surrogate marker for monitoring the starting time for PBSC collection. Applying cutoff values for the number of HPC and CD34+ cells may be clinically useful for optimizing the timing of PBSC collection.

Keywords: CD34+ cells; apheresis; autologous; hematopoietic progenitor cells; peripheral blood stem cell.

MeSH terms

  • Adult
  • Aged
  • Blood Component Removal / methods*
  • Female
  • Hematopoietic Stem Cell Mobilization / methods*
  • Humans
  • Lymphoma / therapy*
  • Male
  • Middle Aged
  • Multiple Myeloma / therapy*
  • Neutrophils
  • Peripheral Blood Stem Cell Transplantation / methods*
  • Retrospective Studies
  • Transplantation, Autologous
  • Young Adult